Cleveland Biolabs: Important Near-Term Catalysts

A New York-based portfolio manager points to several pending developments that can move Cleveland Biolabs stock (NASDAQ: CBLI, $7.44). A BARDA grant is one potential near-term catalyst. Other catalysts possible later this year include the HHS issuing an RFP for an anti-radiation drug where we may learn how much the agency plans to allocate for an emergency stockpile, the company starting trials with its CBLB502 drug seeking to reduce negative side effects of radiation treatment on cancer patients, and publication of research papers.